차세대 염기서열 분석 시장 : 기술별, 제품 유형별, 리드장별, 최종사용자별, 용도별 - 시장 예측(2026-2032년)

The Next Generation Sequencing Market is projected to grow by USD 37.48 billion at a CAGR of 16.72% by 2032.

Next generation sequencing has moved from a specialized research workflow into a core infrastructure layer for precision medicine, oncology, inherited disease testing, infectious disease surveillance, reproductive health, pharmacogenomics, agriculture, and biomanufacturing. The market is supported by verified advances in sequencing chemistry, library preparation, laboratory automation, and cloud-based bioinformatics that have reduced turnaround time while increasing throughput, scalability, and read accuracy.

Demand is strongest where NGS links directly to clinical utility, reimbursement readiness, drug development productivity, and public health value. Cancer profiling, rare disease diagnosis, liquid biopsy research, pathogen genomics, newborn screening research, and population-scale sequencing programs continue to expand adoption as laboratories seek scalable platforms that combine reliable data generation with validated interpretation and secure data management.

Transformative Shifts Reshaping Next Generation Sequencing

The NGS landscape is being reshaped by three structural shifts: the move from short-read dominance to a mixed short-read and long-read ecosystem, the migration of analysis from local servers to secure cloud and hybrid environments, and the integration of sequencing into routine clinical decision-making. High-throughput instruments now support population-scale projects, while benchtop and mid-throughput systems enable decentralized testing in hospital, regional, and specialty laboratories.

Long-read sequencing is gaining adoption for structural variants, repeat expansions, haplotype phasing, genome assembly, and metagenomics, while short-read platforms remain essential for cost-efficient oncology panels, exomes, transcriptomes, and high-volume sample processing. At the same time, regulatory-grade software, laboratory automation, sample-to-report workflows, interoperability, and quality management are becoming competitive differentiators as buyers prioritize reproducibility, compliance, and operational efficiency.

Cumulative Impact of Artificial Intelligence in NGS

Artificial intelligence is compounding the value of NGS by improving base calling, variant prioritization, annotation, quality control, and clinical interpretation. AI-enabled tools help reduce manual curation burden, identify sequencing artifacts, detect complex patterns in genomic and transcriptomic data, and accelerate the interpretation of large-scale genomic, epigenomic, and multiomic datasets.

The most significant impact is cumulative: each additional validated dataset can improve model performance, while each automated workflow can reduce turnaround time and cost per insight. In clinical environments, AI is particularly valuable for triaging variants of uncertain significance, linking genomic findings to phenotype data, supporting molecular tumor boards, and strengthening decision support. Governance remains critical, as algorithms must be validated, auditable, explainable where required, and aligned with privacy, cybersecurity, and medical-device requirements.

Key Regional Insights

North America remains a leading NGS region because of strong academic medical centers, advanced reference laboratory networks, biomedical funding, clinical trial activity, and broad adoption of oncology, rare disease, pharmacogenomics, and infectious disease sequencing. Europe benefits from national genomics strategies, mature biobank assets, cancer and rare disease programs, and regulation-led emphasis on data protection and clinical quality, with health-data initiatives expected to improve responsible cross-border data use over time.

Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and ASEAN economies invest in precision medicine, reproductive genomics, oncology testing, population genomics, and infectious disease surveillance. Latin America shows rising demand in Brazil and Mexico, supported by private diagnostics, academic collaborations, and expanding molecular laboratory capacity. The Middle East is advancing through national genome programs, preventive health strategies, and specialist hospital infrastructure, especially in Gulf countries, while Africa is building sequencing capacity through pathogen surveillance, human genomics initiatives, antimicrobial resistance monitoring, and regional research networks that improve genomic representation.

Key Group Insights

Among major economic and geopolitical groups, the G7 continues to lead in clinical adoption, reimbursement development, regulatory science, genomic medicine programs, and advanced sequencing infrastructure. The European Union is distinguished by coordinated health-data policy, genomics networks, rare disease collaboration, cancer mission priorities, and harmonized quality frameworks that support cross-country research and clinical implementation.

BRICS economies are increasingly important for high-volume sequencing demand, local manufacturing ambitions, biopharmaceutical research, and large-population genomic diversity. ASEAN markets are at varied stages, with Singapore and Thailand moving faster in clinical genomics and precision medicine adoption, while Indonesia, Vietnam, Malaysia, and the Philippines continue to expand laboratory capacity and workforce skills. GCC countries are investing in national genome initiatives, preventive medicine, population health, and specialized diagnostics, while NATO members benefit from strong biomedical research systems, biosecurity priorities, defense-related public health preparedness, and infectious disease surveillance capabilities.

Key Country Insights

The United States is a major NGS commercialization hub, supported by advanced diagnostics, biopharma demand, academic medicine, public health genomics, and large population research programs. Canada contributes through cancer genomics, newborn and rare disease initiatives, and publicly supported research networks, while Mexico and Brazil are strengthening private diagnostics, oncology testing access, and academic sequencing networks across Latin America.

In Europe, the United Kingdom, Germany, and France lead through national genomics programs, cancer strategies, rare disease frameworks, and industrial biotechnology capacity, while Italy and Spain are expanding hospital-based molecular testing and translational genomics. Russia maintains scientific capability in genomics and molecular biology but faces procurement, funding, and international collaboration constraints. In Asia-Pacific, China has substantial sequencing scale and population genomics activity, India is growing through affordability, disease diversity, and expanding diagnostic access, Japan and South Korea emphasize high-quality clinical adoption, oncology genomics, and advanced research infrastructure, and Australia supports genomics through public health programs, rare disease research, cancer genomics, and national research infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize workflows that deliver measurable clinical, operational, or research outcomes rather than competing only on sequencing cost. Commercial success increasingly depends on end-to-end solutions that integrate sample preparation, sequencing, bioinformatics, reporting, data security, interoperability, quality assurance, and regulatory documentation.

Executives should build partnerships with hospitals, reference laboratories, biopharmaceutical developers, public health agencies, and national genomics programs to secure high-value use cases. Investment should focus on automation, AI-assisted interpretation, reimbursement evidence, decentralized testing support, workforce training, data governance, and compliance with evolving privacy, cybersecurity, and diagnostic regulations. Organizations that combine platform performance with trusted data interpretation, validated clinical evidence, and regionally adapted deployment models will be best positioned for durable growth.

Research Methodology

This executive summary is developed using secondary research from verified public sources, including regulatory agencies, national genomics programs, public health organizations, peer-reviewed literature, clinical guideline bodies, reimbursement references, government health-data initiatives, and published scientific collaborations. Market interpretation emphasizes documented technology adoption, policy direction, clinical use cases, regulatory context, and infrastructure investment.

The analysis applies a triangulated approach that compares platform trends, regional healthcare capacity, reimbursement maturity, research funding, regulatory readiness, laboratory infrastructure, and end-user demand across clinical diagnostics, pharmaceutical research, public health, agriculture, and academic genomics. Insights are synthesized to identify structural drivers, constraints, and strategic priorities without relying on unverified claims, market sizing, market share estimates, or unsupported projections.

Conclusion

Next generation sequencing is becoming a foundational technology for data-driven healthcare and life sciences. The market is no longer defined only by sequencing speed or cost; it is increasingly defined by the ability to convert genomic data into reliable, actionable, secure, and compliant decisions across clinical, research, public health, and industrial applications.

Adoption will be strongest where platforms, software, clinical evidence, reimbursement pathways, quality systems, and data governance align. As AI, long-read sequencing, multiomics, spatial biology, and population genomics mature, industry leaders that deliver validated workflows and regionally adapted strategies will be positioned to capture the highest-value opportunities in the global NGS ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Next Generation Sequencing Market, by Technology

• 7.1. Amplicon Sequencing
• 7.2. Gene Panel Sequencing
• 7.3. RNA Sequencing
• 7.4. Targeted Sequencing
• 7.5. Whole Exome Sequencing (WES)
• 7.6. Whole Genome Sequencing (WGS)

8. Next Generation Sequencing Market, by Product Type

• 8.1. Consumables Reagents
  • 8.1.1. Enzymes
  • 8.1.2. Kits
• 8.2. Instruments
  • 8.2.1. Ancillary Instruments
  • 8.2.2. Sequencers
• 8.3. Software
• 8.4. Services

9. Next Generation Sequencing Market, by Read Length

• 9.1. Short-Read
• 9.2. Long-Read

10. Next Generation Sequencing Market, by End User

• 10.1. Academic Research Institutes
• 10.2. Healthcare Diagnostic Laboratories
• 10.3. Pharmaceutical Biotechnology Companies

11. Next Generation Sequencing Market, by Application

• 11.1. Agrigenomics
• 11.2. Epigenomics
• 11.3. Forensic Genomics
• 11.4. Neurogenomics
• 11.5. Oncology
• 11.6. Pharmacogenomics

12. Next Generation Sequencing Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Next Generation Sequencing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Next Generation Sequencing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Illumina, Inc.
• 16.2. Thermo Fisher Scientific, Inc.
• 16.3. QIAGEN N.V.
• 16.4. BGI Genomics Co., Ltd.
• 16.5. Oxford Nanopore Technologies plc.
• 16.6. Agilent Technologies, Inc.
• 16.7. Bio-Rad Laboratories, Inc.
• 16.8. Takara Bio Inc.
• 16.9. Eurofins Genomics GmbH
• 16.10. Pacific Biosciences of California, Inc.
• 16.11. F. Hoffmann-La Roche Ltd
• 16.12. Novogene Co., Ltd.
• 16.13. MGI Tech Co., Ltd.
• 16.14. GenScript Biotech Corporation
• 16.15. 10x Genomics, Inc.
• 16.16. DNAnexus, Inc.
• 16.17. Element Biosciences, Inc.
• 16.18. Fabric Genomics, Inc.
• 16.19. Integrated DNA Technologies, Inc.
• 16.20. Macrogen, Inc.
• 16.21. PerkinElmer, Inc.
• 16.22. PierianDx, Inc.
• 16.23. SeqWell, Inc.
• 16.24. Singular Genomics Systems, Inc.
• 16.25. Strand Life Sciences Pvt. Ltd.
• 16.26. Ultima Genomics, Inc.